KRKaushik Rajaram

Kaushik Rajaram

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kaushik Rajaram has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Harnessing phage-ciprofloxacin synergy to overcome multidrug-resistant infections and biofilm persistence

    by Nashath Kalangadan, Srivignesh Sundaresan, Abishek Mani, Nandhakumar Muruganandham, Siji Siju, Sutharsan Govindarajan, Kaushik Rajaram


  • Restoring ciprofloxacin efficacy via β-caryophyllene synergy for concurrent infection control and tissue regeneration

    by Nashath Kalangadan, Abishek Mani, Srivignesh Sundaresan, Arumuka Pravin Iyadurai, Sutharsan Govindarajan, Kaushik Rajaram

    The occurrence of antimicrobial-resistant microbial infection on the wounds are considered a critical issue in delayed or non-healing wounds. Due to the scarcity of new antibiotics in the market, alternate combinational therapies are gaining interest in tackling this issue. In this study, we investigate the antimicrobial efficacy of ciprofloxacin (CIP) enhanced by the adjuvant activity of beta-caryophyllene (BCP), an efflux pump inhibitor harnessing their synergistic potential to achieve improved wound healing activity. The synergistic effect of CIP and BCP was assessed for its antimicrobial activity and evaluated for wound healing and infection control in both in vitro and in ovo models. The non-cytotoxic concentration of BCP (80 µg/mL) and varying concentrations of CIP (1.25–10 µg/mL) combination effectively reduced CIP’s minimum inhibitory concentration by half and disintegrated biofilms of Staphylococcus aureus and Enterococcus faecalis. The combination increased fibroblast cell migration by 20% in in vitro compared to untreated samples. The BCP treatment modulated key wound-healing-associated genes, with upregulation of TGF-β, COL1A1, COL3A1, and FGF2, and downregulation of IL-1β and MMP-2, indicating profound wound healing activity. In the in ovo infection model, it achieved a 100% survival rate and additionally led to a 45% increase in vessel length and a 60% rise in vessel junctions in angiogenesis studies. Therefore, the combinational therapy of CIP and BCP demonstrated a dual role by effectively managing infections caused by multidrug-resistant wound pathogens and promoting wound healing. Remarkably, this approach reduced CIP dosage by 50%, thereby lowering antibiotic selective pressure and yielded complete killing of pathogens. Graphical Abstract


  • Open Access

    Effect of light spectrum and photoperiod on growth and phytochemicals of Amaranthus microgreens

    by Sri Harini Ramalingam, Arumuka Pravin Iyadurai, Gomathi Arivalagan, Divyabharathi M.C., Rama Krishna Karri, Ramesh Kumar Alagarsamy, Kaushik Rajaram, Srivignesh Sundaresan


  • Open Access

    Probiotic biogenics-mediated augmentation of phage therapy against multidrug-resistant Enterotoxigenic Escherichia coli

    by Abishek Mani, Nashath Kalangadan, Sharayu Magar, Barath Sivaraj, Gospel Gabriel Xavier, Thirumalai Diraviyam, Srivignesh Sundaresan, Sutharsan Govindarajan, Kaushik Rajaram

    Enterotoxigenic Escherichia coli (ETEC) is one of the most common causative agents of foodborne gastroenteritis globally, spreading through contaminated water and food. The rising incidence of multidrug-resistant (MDR) bacteria has produced an urgent need for alternative antimicrobial treatments. Bacteriophages are potential therapeutic agents against MDR infections; yet, the development of phage resistance remains a critical limitation to their clinical applications. In this study, we isolated and characterized an ETEC-targeting lytic bacteriophage (CU10EC) with potent antibacterial activity. Phage resistance was observed within ~10 h of treatment, making phage therapy ineffective. To address this limitation, we used a novel combinatorial approach that combined cell free probiotic biogenics (PB) produced by the probiotic bacterium Lactobacillus acidophilus with CU10EC-mediated therapy. The PB contains a rich array of biomedically relevant components, including organic acids, antimicrobial peptides, short-chain fatty acids, and proteolytic enzymes, as confirmed by LC-MS analysis. It demonstrated effective antibacterial activity against MDR-ETEC, broad-spectrum activity against other pathogens, and less or no antibacterial activity against commensals. Importantly, in the presence of phage CU10EC, only two-thirds of the PB concentration was required for complete bacterial killing. Additionally, the consecutive administration of PB at 2, 4, and 6 h in a time-kill assay delayed phage resistance by 6–10 h. Overall, the CU10EC-PB combination offers a novel method to enhance antibacterial activity, while conserving gut commensals and delaying phage resistance.

  • Open Access

    Augmenting phage therapy using green nanotechnology for promising infection control, wound healing and devoiding phage resistance in MDR Pseudomonas aeruginosa

    by Abishek Mani, Aarcha Shanmugha Mary, Nashath Kalangadan, Srivignesh Sundaresan, Somnath Ghosh, John Prakash, Siva Sundara Kumar Durairajan, Kaushik Rajaram

    Humanity could descend into a pre-antibiotic world as a result of antimicrobial resistance (AMR). Phage defenses are considered “vintage heroes” in the battle against multidrug-resistant (MDR) bacteria. However, phage resistance continues to evolve, necessitating alternative strategies. A potential solution is combining phages with antimicrobials like silver nanoparticles (AgNPs) to enhance the phage therapy. This study focuses on a combination therapy using Bauhinia variegata L.-mediated AgNPs and Pseudomonas phage M12PA to target multidrug-resistant (MDR) Pseudomonas aeruginosa. The antibacterial properties of this combination were evaluated through comprehensive characterizations and assays. As a proof of concept, the AgNP-phage combination delayed phage resistance by 6–12 h, reduced mutation, and enhanced antibacterial efficiency. Anti-biofilm activity improved by ~ 40% compared to AgNPs alone at sub-inhibitory concentrations. AgNPs and phages have demonstrated excellent compatibility, and the phage titer did not drop noticeably over 30 days. Biocompatibility assessments, including cell viability and hemolysis assays, highlighted the safety of biosynthesized AgNPs. Wound healing efficacy was also demonstrated in mouse fibroblast cells and an in ovo angiogenesis model. This study underscores the efficiency of phage-AgNPs synergy to be a potential therapeutic approach for MDR bacterial wound infection, showing effective anti-biofilm activity, delayed phage resistance, and minimal toxicity.


  • Open Access

    Relative fitness of wild-type and phage-resistant pyomelanogenic P. aeruginosa and effects of combinatorial therapy on resistant formation

    by Aarcha Shanmugha Mary, Nashath Kalangadan, John Prakash, Srivignesh Sundaresan, Sutharsan Govindarajan, Kaushik Rajaram


  • Formulation of Dual-Functional Nonionic Cetomacrogol Creams Incorporated with Bacteriophage and Human Platelet Lysate for Effective Targeting of MDR P. aeruginosa and Enhanced Wound Healing

    by Aarcha Shanmugha Mary, Maruthupandy Muthuchamy, Muneeswaran Thillaichidambaram, Sinuk Lee, Barath Sivaraj, Sharayu Magar, Somnath Ghosh, Chitrali Laha Roy, Srivignesh Sundaresan, Meganathan Kannan, et al.

    Successful development of phage-based therapeutics and their utility predominantly depend on the mode and route of phage administration. Topical and site-directed phage application evokes minimal immune clearance and allows more phage-host adsorption, thereby ensuring higher phage efficacy. However, a notable drawback of conventional topical phage applications is the absence of sustained release. Occlusive emollients guarantee the controlled release of active pharmaceutical ingredients (APIs), thereby facilitating administration, preventing moisture loss, and acting as a skin barrier. In this study, we developed phage and human platelet lysate (h-PL) incorporated cetomacrogol-based creams for combined phage therapy and wound healing. The base material for phage immobilization was formulated by emulsifying paraffin and sterile water with cetomacrogol (emulsifying agent). Specifically, we incorporated a Pseudomonas aeruginosa-infecting lytic phage vB_PaeM_M12PA in the formulation and characterized its genome in this study. Cetomacrogol, a nonionic PEG (polyethylene glycol) based ether, rendered phage stability and allowed initial burst release followed by continuous controlled release of phages from the embedding matrix in the initial 6-8 h. Rheological studies showed that the material has elastic properties with storage moduli (G') values ranging from 109.51 ± 2.10 to 126.02 ± 3.13 kPa, indicating frequency-independent deformation. Platelet lysates in the cream acted as wound healing agents, and in vitro evaluation of cell migration and wound healing capacity of h-PL showed a significant enhancement by the sixth hour compared to untreated groups. The phage-incorporated cream showed sustained phage release in solid media and a significant reduction in bacterial growth in liquid cultures. In vivo wound healing studies in 6-week-old Wistar rats with full-thickness excision wounds and subsequent histopathological studies showed that the formulation enhanced wound healing and tissue restoration efficiency. In conclusion, the study unveils a promising approach for integrated phage therapy and wound healing strategies.


  • Open Access

    Machine Learning Mediated Advanced Phage and Antimicrobial Therapy- A Futuristic Approach

    by Aarcha Shanmugha Mary, Manali Manik Patil, Godhuli Kundu, Kaushik Rajaram

    The emergence of antimicrobial resistance (AMR) has overwhelmed the contemporary curatives and have turned into one of the major challenges in the biomedical sector. With increasing deaths being associated with AMR every year; early detection of pathogens and development of novel drugs and alternative therapies, have all become ad hoc in diagnosis, prognosis and patient survival. Bacteriophage therapy remains a viable strategy to counteract AMR, yet unduly restrained by phage resistance. Phage infection is a natural phenomenon and can be widely manipulated in vitro using advanced techniques including the CRISPR/Cas systems which renders phage therapy an upper hand in comparison to conventional drugs. Phage identification, host range detection, determination of phage-receptor binding efficiency, adsorption rate, phage genome analysis are crucial stages in phage selection and phage cocktail preparation and moreover pivotal in flourishing phage therapy. The ascent of translational research and omics has allowed the development of quick, reliable and precise strategies for phage-based diagnosis and treatment techniques. However, in vitro evaluation of AMR and phage factors as well as storing, processing and analyzing large laboratory data outputs are expensive, time-consuming and labor-intensive. Machine learning (ML) is a utilitarian strategy to organize, store, analyze data sets and more importantly allows prediction of certain features by recognizing patterns in the data sets. With the huge number of research been carried out around the globe and enormous data sets being published and stored in databases, ML can utilize the available data to perform and guide in developing alternative therapeutics. Several ML based tools have been developed to predict resistance in host, phage grouping for cocktail preparation, resistance and lysogenic genes detection, phage genomic evaluation and to understand phage-host interactions. ML also allows the in silico analysis of large samples (drug/phage) and reduces sample size for in vitro evaluation thereby reducing overall costs, time and labor. The present review summarizes the available ML algorithms and corresponding databases used in AMR and phage research. It also emphasizes the status quo of antimicrobial and phage resistance in the healthcare sector and analyses the role of ML in analyzing biological databases in order to predict possible phage/drug-host interaction patterns, phage susceptibility, suitability of phage strains for therapy and recommends the most efficient drug combinations and treatment strategies.


  • Repurposing ivermectin and ciprofloxacin in nanofibers for enhanced wound healing and infection control against MDR wound pathogens

    by Nashath Kalangadan, Aarcha Shanmugha Mary, Kaushik Mani, Biplab Nath, Jayalalitha Kondapalli, Swati Soni, Vikram Srinivasa Raghavan, Rajesh Parsanathan, Meganathan Kannan, David Jenkins, et al.